Global Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, and Upper Extremity), Age Group (Adult, Pediatric and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others) - Industry Trends and Forecast to 2030.
Lymphedema Treatment Market Analysis and Insights
Lymphedema is incurable, but with the right treatment, it can be controlled through treatment which can help reduce the swelling and pain. The global lymphedema treatment market is growing in the forecast year due to the rising players in the market and the availability of advanced imaging products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market. The rising number of cancer related lymphedema patients worldwide and the increased R&D activities are propelling the demand for the global lymphedema treatment market in the forecast period. However, no cure and high cost of treatment may hamper the growth of the global lymphedema treatment market in the forecast period.
Data Bridge Market Research analyzes that the global lymphedema treatment market is expected to reach a value of USD 1,866,576.80 thousand by 2030, at a CAGR of 9.8% during the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, and Upper Extremity), Age Group (Adult, Pediatric and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, United Kingdom, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Austria. Hungary, Norway, Ireland, Lithuania, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
medi GmbH & Co. KG, PAUL HARTMANN AG, 3M, Convatec Inc., JUZO, SIGVARIS GROUP, Sanyleg Srl a socio unico, AIROS Medical, Inc., Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd., ThermoTek, Cardinal Health, Essity (BSN medical GmbH), Smith+Nephew HERANTIS PHARMA Plc, Huntleigh Healthcare Limited, Avet Pharmaceuticals Inc, KOYA MEDICAL among others
|
Global Lymphedema Treatment Market Definition
Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals.
Lymph nodes are an important part of your lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage your lymph nodes. Any type of problem that blocks the drainage of lymph fluid can cause lymphedema. Treatment may include compression bandages, massage, compression stockings, sequential pneumatic pumping, careful skin care, and, rarely, surgery to remove swollen tissue or to create new drainage routes. The high prevalence of cancers, increasing innovations and technologies rising number of players in the market, and novel product launches are also propelling the growth of the global lymphedema treatment market.
Global Lymphedema Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Cancer
Breast cancer arises in the lining cells (epithelium) of the ducts (85%) or lobules (15%) in the glandular tissue of the breast. Initially, the cancerous growth is confined to the duct or lobule (“in situ”) where it generally causes no symptoms and has minimal potential for spread (metastasis).
Patients undergoing axillary surgery and/or axillary radiation therapy for breast cancer are at higher risk of developing lymphedema of the arm. The previous convention suggested that nodal positivity was a predisposing factor for the development of lymphedema in breast cancer patients. The aspect would become a driving force for the market growth.
- Availability of Multiple Therapies for Lymphedema
Lymphedema treatment involves multiple therapies instead of a standard treatment since the patients are dissatisfied or don’t get cured with the conventional treatment of lymphedema. They approach the alternative treatment which offers more control over health care decisions, and the alternatives are found to be more compatible with the patient’s health system. The alternative therapies would result in better treatment for lymphedema patients. It would improve the patient-reported outcome. Therefore, these alternative therapy options are accelerating market growth.
Restraint/Challenges
- High Treatment Costs
Lymphedema not only causes pain and limits a patient's activities of daily living but also directly impacts the financial costs to the individual through co-payments for increased medical and therapist consultations and the direct costs of compression garments and other treatment-related medical expenses. Lymphedema also increases the impact on employment and career, which can also affect finances. As the cost of laser treatment and surgery is expensive. Therefore, the healthcare centers and healthcare community centers, face hindrances in purchasing the product (drug or medical device) due to low economic financials, limiting the sales of devices and their accessories. It would limit the supply chain production. This factor can act acting as a restraint for the global lymphedema treatment market.
Opportunity
- Increasing Drug Approvals
The global lymphedema treatment market has witnessed numerous drug approvals in past years driven by the increasing fatality rate of the disease. Increasing drug approvals will ramp up the demand for the lymphedema treatment market. Increasing regulatory endorsements for lymphedema-related drugs and recombinant products will constitute an increase in global lymphedema treatment market value in the coming years. Thus, the companies are increasing their product portfolio with combination drug products to enhance their business in various dimensions. Therefore, increasing drug approvals can be a great opportunity for Global lymphedema treatment market growth.
Recent Developments
- In June 2021, InfuSystem Holdings, Inc. announced that it has entered into a joint agreement with Bio Compression Systems, Inc. whereby InfuSystem will add Lymphedema Therapy to its Integrated Therapy Service (“ITS”) platform facilities. This boosted sales of both companies thereby helping in revenue generation.
- In September 2020, Paul Hartmann AG formed partnerships with Apollo Hospitals Group in India and West China Hospital to focus on the operation of wound care clinics and ambulances, medical training, and products and services. This step helped the company to spread its wings in the Asia-Pacific market.
- In April 2020, L&R Group enhanced its position in the compression market - L&R acquired assets of French compression expert MTA. This acquisition allowed L&R to expand its product portfolio for venous insufficiency and lymphedema treatments and thus strengthened its market position in France.
- In August 2019, Paul Hartmann AG announced the acquisition of Safran Coating from Safran SA. This acquisition helped the company to increase its product portfolio.
- In September 2018, SIGVARIS announced the introduction of SECURE, an innovative garment featuring graduated compression and containment properties for the management of advanced venous edema, lymphedema, post-surgical edema, and general edema. This app launch boosted the market growth by creating awareness among people.
Global Lymphedema Treatment Market Scope
The global lymphedema treatment market is categorized into seven notable segments which are based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Treatment Type
- Compression Therapy
- Surgery
- Drug Therapy
- Laser Therapy
- Others
On the basis of treatment type, the market is segmented into compression therapy, surgery, drug therapy, laser therapy, and others.
Type
- Secondary Lymphedema
- Primary Lymphedema
On the basis of type, the market is segmented into secondary lymphedema and primary lymphedema.
Affected Area
- Lower Extremity
- Upper Extremity
- Genitalia
On the basis of the affected area, the global lymphedema treatment market is segmented into lower extremity, upper extremity, and genitalia.
Age Group
- Adult
- Geriatric
- Pediatric
On the basis of age group, the market is segmented into adult, geriatric, and pediatric.
Route of Administration
- Oral
- Injectable
- Topical
On the basis of route of administration, the market is segmented into oral, injectable, and topical.
End User
- Hospital
- Speciality Clinics
- Ambulatory Surgical Centers
- Others.
On the basis of end user, the market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others.
Distribution Channel
- Pharmacy Stores
- Direct Tender
- Others
On the basis of distribution channel, the market is segmented into pharmacy stores, direct tender, and others.
Global Lymphedema Treatment Market Regional Analysis/Insights
The global lymphedema treatment market is categorized into seven notable segments which are based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, United Kingdom, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Austria. Hungary, Norway, Ireland, Lithuania, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa.
North America is expected to dominate the market due to the rising cases of lymphedema and other related issues among the population. The U.S. dominates North America region due to strong presence of key players. Germany is expected to dominate Europe region due to the increasing demand from emerging markets and expansion. China dominates the Asia-Pacific region due to due to the availability of multiple therapies for lymphedema.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Lymphedema Treatment Market Share Analysis
The global lymphedema treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global lymphedema treatment market.
Some of the key players operating in the global lymphedema treatment market are medi GmbH & Co. KG, PAUL HARTMANN AG, 3M, Convatec Inc., JUZO, SIGVARIS GROUP, Sanyleg Srl a socio unico, AIROS Medical, Inc., Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd., ThermoTek, Cardinal Health, Essity (BSN medical GmbH), Smith+Nephew HERANTIS PHARMA Plc, Huntleigh Healthcare Limited, Avet Pharmaceuticals Inc, and KOYA MEDICAL among others.
SKU-